mayo clinic glp-1 Primary Care in Rochester and Kasson GLP-1s and Aging: Risks, Benefits

Description

This is followed by the release of nesfatin-1 which stimulates cholecystokinin secretion leading to a rise in bile salts from gallbladder emptying, and the binding of Takeda P protein coupled receptor 5 (TGR5) onto the surface of the enteroendocrine cells, all of which eventually culminates in GLP-1 secretion [9]

In response to hyperglycemia, GIP exhibits no effect on glucagon responses while potentiating insulin secretion

95% CI, 1.26-1.56), but shorter duration (=26 weeks) of treatment was not (RR 0.79)

GLP-1 medications also carry an FDA black box warning for risk of thyroid C-cell tumors, and should not be used by patients with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 (MEN2)

Several small molecules targeting the APJ receptor have progressed to clinical evaluation but were discontinued due to insufficient superiority over the standard of care